Table 2.
Comparison of outcome measures by pretreatment features and primary treatment.
| Outcome measures | ||||||
|---|---|---|---|---|---|---|
| 5-year OS | P value1 | 5-year BFFS | P value1 | 5-year CSS | P value1 | |
| Gleason score | ||||||
| 8 | 77.2% | 0.71 | 75.6% | <0.001 | 96.1% | 0.001 |
| 9 | 74% | 58.2% | 95.9% | |||
| 10 | 70.6% | 41.2% | 76.5% | |||
| Pretreatment PSA (ng/mL) | ||||||
| <10 | 80.7% | 0.002 | 72.1% | 0.001 | 98% | <0.001 |
| 10–20 | 83.3% | 61.1% | 100% | |||
| >20 | 63.6% | 51.1% | 84.1% | |||
| Extent of disease at diagnosis | ||||||
| Unilateral | 79.7% | 0.53 | 67.8% | 0.54 | 97.2% | 0.28 |
| Bilateral | 77% | 64.9% | 95% | |||
| Percentage of positive cores | ||||||
| <50% | 79.8% | 0.30 | 71.3% | 0.02 | 95.7% | 0.69 |
| ≥50% | 75.5% | 60.6% | 94.9% | |||
| Months from diagnosis to treatment | ||||||
| <3 | 76.5% | 0.08 | 62.6% | 0.29 | 94.2% | 0.43 |
| 3–12 | 81.6% | 70.2% | 97.2% | |||
| >12 | 60% | 70% | 95% | |||
1OS: Overall Survival; BFFS: Biochemical Failure-Free Survival; MFS: Metastasis-Free Survival; CSS: Cancer-Specific Survival.
2Pearson's Chi-Square test.